Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1027

1.

The IL-1 family of cytokines and receptors in rheumatic diseases.

Dinarello CA.

Nat Rev Rheumatol. 2019 Oct;15(10):612-632. doi: 10.1038/s41584-019-0277-8. Epub 2019 Sep 12. Review.

PMID:
31515542
2.

Targeting innate immune mediators in type 1 and type 2 diabetes.

Donath MY, Dinarello CA, Mandrup-Poulsen T.

Nat Rev Immunol. 2019 Sep 9. doi: 10.1038/s41577-019-0213-9. [Epub ahead of print] Review.

PMID:
31501536
3.

IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.

Højen JF, Kristensen MLV, McKee AS, Wade MT, Azam T, Lunding LP, de Graaf DM, Swartzwelter BJ, Wegmann M, Tolstrup M, Beckman K, Fujita M, Fischer S, Dinarello CA.

Nat Immunol. 2019 Sep;20(9):1138-1149. doi: 10.1038/s41590-019-0467-1. Epub 2019 Aug 19.

PMID:
31427775
4.

The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis.

Madonna S, Girolomoni G, Dinarello CA, Albanesi C.

Int J Mol Sci. 2019 Jul 5;20(13). pii: E3318. doi: 10.3390/ijms20133318. Review.

5.

Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis.

Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Meyers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, Jordan CT, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM.

Haematologica. 2019 May 17. pii: haematol.2018.197210. doi: 10.3324/haematol.2018.197210. [Epub ahead of print]

6.

Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome.

Osborne DG, Domenico J, Luo Y, Reid AL, Amato C, Zhai Z, Gao D, Ziman M, Dinarello CA, Robinson WA, Fujita M.

Mol Carcinog. 2019 Sep;58(9):1670-1679. doi: 10.1002/mc.23044. Epub 2019 May 16.

PMID:
31099111
7.

Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.

Mantovani A, Dinarello CA, Molgora M, Garlanda C.

Immunity. 2019 Apr 16;50(4):778-795. doi: 10.1016/j.immuni.2019.03.012. Review.

PMID:
30995499
8.

Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases.

Cavalli G, Dinarello CA.

Front Pharmacol. 2019 Mar 8;10:148. doi: 10.3389/fphar.2019.00148. eCollection 2019.

9.

Interleukin-37 monomer is the active form for reducing innate immunity.

Eisenmesser EZ, Gottschlich A, Redzic JS, Paukovich N, Nix JC, Azam T, Zhang L, Zhao R, Kieft JS, The E, Meng X, Dinarello CA.

Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5514-5522. doi: 10.1073/pnas.1819672116. Epub 2019 Feb 28.

10.

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.

Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, Dagna L.

Arthritis Res Ther. 2019 Feb 25;21(1):69. doi: 10.1186/s13075-019-1850-x.

11.

Role for nuclear interleukin-37 in the suppression of innate immunity.

Li S, Amo-Aparicio J, Neff CP, Tengesdal IW, Azam T, Palmer BE, López-Vales R, Bufler P, Dinarello CA.

Proc Natl Acad Sci U S A. 2019 Feb 21. pii: 201821111. doi: 10.1073/pnas.1821111116. [Epub ahead of print]

12.

Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.

Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, Dagna L.

Arthritis Res Ther. 2019 Feb 13;21(1):54. doi: 10.1186/s13075-019-1843-9. No abstract available. Erratum in: Arthritis Res Ther. 2019 Feb 25;21(1):69.

13.

Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression.

Cleophas MCP, Crişan TO, Klück V, Hoogerbrugge N, Netea-Maier RT, Dinarello CA, Netea MG, Joosten LAB.

Arthritis Res Ther. 2019 Feb 6;21(1):50. doi: 10.1186/s13075-019-1834-x.

14.

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer.

Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J.

Oncoimmunology. 2018 Dec 12;8(3):1551651. doi: 10.1080/2162402X.2018.1551651. eCollection 2019.

15.

Interleukin-1α as an intracellular alarmin in cancer biology.

Voronov E, Dinarello CA, Apte RN.

Semin Immunol. 2018 Aug;38:3-14. doi: 10.1016/j.smim.2018.10.006. Epub 2018 Oct 26. Review. No abstract available.

PMID:
30554608
16.

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.

Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, Dinarello CA, Voronov E, Apte RN.

Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369. doi: 10.1073/pnas.1812266115. Epub 2018 Dec 13.

17.

Anakinra Therapy for Non-cancer Inflammatory Diseases.

Cavalli G, Dinarello CA.

Front Pharmacol. 2018 Nov 6;9:1157. doi: 10.3389/fphar.2018.01157. eCollection 2018. Review. Erratum in: Front Pharmacol. 2019 Mar 08;10:148.

18.

The Inter-Relationship of Platelets with Interleukin-1β-Mediated Inflammation in Humans.

Tunjungputri RN, Li Y, de Groot PG, Dinarello CA, Smeekens SP, Jaeger M, Doppenberg-Oosting M, Cruijsen M, Lemmers H, Toenhake-Dijkstra H, Aguirre-Gamboa R, Kumar V, Wijmenga C, Joosten LAB, Netea MG, van der Ven A, de Mast Q.

Thromb Haemost. 2018 Dec;118(12):2112-2125. doi: 10.1055/s-0038-1675603. Epub 2018 Nov 19.

PMID:
30453346
19.

IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.

Mercurio L, Morelli M, Scarponi C, Eisenmesser EZ, Doti N, Pagnanelli G, Gubinelli E, Mazzanti C, Cavani A, Ruvo M, Dinarello CA, Albanesi C, Madonna S.

Cell Death Dis. 2018 Oct 30;9(11):1104. doi: 10.1038/s41419-018-1143-3.

21.

TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization.

Wade MF, Collins MK, Richards D, Mack DG, Martin AK, Dinarello CA, Fontenot AP, McKee AS.

J Immunol. 2018 Oct 15;201(8):2232-2243. doi: 10.4049/jimmunol.1800303. Epub 2018 Sep 5.

22.

The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6.

Tengesdal IW, Kitzenberg D, Li S, Nyuydzefe MS, Chen W, Weiss JM, Zhang J, Waksal SD, Zanin-Zhorov A, Dinarello CA.

Eur J Immunol. 2018 Oct;48(10):1679-1686. doi: 10.1002/eji.201847652. Epub 2018 Sep 21.

23.

NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis.

Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, de Graaf DM, Dinarello CA, Joosten LAB.

Arthritis Res Ther. 2018 Aug 3;20(1):169. doi: 10.1186/s13075-018-1664-2.

24.

Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition.

De Luca G, Campochiaro C, Dinarello CA, Dagna L, Cavalli G.

Ann Intern Med. 2018 Dec 4;169(11):819-820. doi: 10.7326/L18-0315. Epub 2018 Jul 31. No abstract available.

PMID:
30073251
25.

IL-37 Expression Reduces Lean Body Mass in Mice by Reducing Food Intake.

Kuipers EN, van Dam AD, Ballak DB, de Wit EA, Dinarello CA, Stienstra R, van Diepen JA, Rensen PCN, Boon MR.

Int J Mol Sci. 2018 Aug 2;19(8). pii: E2264. doi: 10.3390/ijms19082264.

26.

Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue.

Ballak DB, Li S, Cavalli G, Stahl JL, Tengesdal IW, van Diepen JA, Klück V, Swartzwelter B, Azam T, Tack CJ, Stienstra R, Mandrup-Poulsen T, Seals DR, Dinarello CA.

J Biol Chem. 2018 Sep 14;293(37):14224-14236. doi: 10.1074/jbc.RA118.003698. Epub 2018 Jul 13.

27.

Indeed, IL-18 is more than an inducer of IFN-γ.

Dinarello CA, Kaplanski G.

J Leukoc Biol. 2018 Aug;104(2):237-238. doi: 10.1002/JLB.CE0118-025RR. Epub 2018 May 7. No abstract available.

28.

Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes.

Damen MSMA, Dos Santos JC, Hermsen R, Adam van der Vliet J, Netea MG, Riksen NP, Dinarello CA, Joosten LAB, Heinhuis B.

Atherosclerosis. 2018 Apr;271:193-202. doi: 10.1016/j.atherosclerosis.2018.02.027. Epub 2018 Mar 2.

29.

Human Interleukin-32γ Plays a Protective Role in an Experimental Model of Visceral Leishmaniasis in Mice.

Gomes RS, Silva MVT, Dos Santos JC, van Linge C, Reis JM, Teixeira MM, Pinto SA, Dorta ML, Bai X, Chan ED, Dinarello CA, Oliveira MAP, Joosten LAB, Ribeiro-Dias F.

Infect Immun. 2018 Apr 23;86(5). pii: e00796-17. doi: 10.1128/IAI.00796-17. Print 2018 May.

30.

Role of glutathione metabolism in host defense against Borrelia burgdorferi infection.

Kerstholt M, Vrijmoeth H, Lachmandas E, Oosting M, Lupse M, Flonta M, Dinarello CA, Netea MG, Joosten LAB.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2320-E2328. doi: 10.1073/pnas.1720833115. Epub 2018 Feb 14.

31.

α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, Riwes MM, Kennel M, Antin JH, Cutler CS, Ho VT, Alyea EP 3rd, Parkin BL, Yanik GA, Choi SW, Lewis EC, Dinarello CA, Koreth J, Reddy P.

Blood. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746. Epub 2018 Feb 2.

32.

Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism.

Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavasin MA, Mahaffey JH, Monzani V, Saripalli C, Mascagni P, Reece TB, Ambardekar AV, Granzier HL, Dinarello CA, McKinsey TA.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaao0144. doi: 10.1126/scitranslmed.aao0144.

33.

OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.

Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, Carta S, Tengesdal I, Nemkov T, D'Alessandro A, Henry C, Jones GS, Goodrich SA, St Laurent JP, Jones TM, Scribner CL, Barrow RB, Altman RD, Skouras DB, Gattorno M, Grau V, Janciauskiene S, Rubartelli A, Joosten LAB, Dinarello CA.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1530-E1539. doi: 10.1073/pnas.1716095115. Epub 2018 Jan 29.

34.

Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation.

Nold-Petry CA, Nold MF, Levy O, Kliger Y, Oren A, Borukhov I, Becker C, Wirtz S, Sandhu MK, Neurath M, Dinarello CA.

Front Immunol. 2017 Dec 11;8:1531. doi: 10.3389/fimmu.2017.01531. eCollection 2017.

35.

Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity.

Dinarello CA.

Immunol Rev. 2018 Jan;281(1):5-7. doi: 10.1111/imr.12624. Review. No abstract available.

36.

Overview of the IL-1 family in innate inflammation and acquired immunity.

Dinarello CA.

Immunol Rev. 2018 Jan;281(1):8-27. doi: 10.1111/imr.12621. Review.

37.

Suppression of inflammation and acquired immunity by IL-37.

Cavalli G, Dinarello CA.

Immunol Rev. 2018 Jan;281(1):179-190. doi: 10.1111/imr.12605. Review.

PMID:
29247987
38.

Biology of IL-38 and its role in disease.

van de Veerdonk FL, de Graaf DM, Joosten LA, Dinarello CA.

Immunol Rev. 2018 Jan;281(1):191-196. doi: 10.1111/imr.12612. Review.

PMID:
29247986
39.

Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease.

Grabherr F, Grander C, Adolph TE, Wieser V, Mayr L, Enrich B, Macheiner S, Sangineto M, Reiter A, Viveiros A, Zoller H, Bufler P, Moschen AR, Dinarello CA, Tilg H.

Liver Int. 2018 Jun;38(6):1095-1101. doi: 10.1111/liv.13642. Epub 2017 Dec 16.

PMID:
29193575
40.

MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.

Kanni T, Argyropoulou M, Spyridopoulos T, Pistiki A, Stecher M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ.

J Invest Dermatol. 2018 Apr;138(4):795-801. doi: 10.1016/j.jid.2017.10.030. Epub 2017 Nov 10.

41.

Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.

Cavalli G, Koenders M, Kalabokis V, Kim J, Choon Tan A, Garlanda C, Mantovani A, Dagna L, Joosten LAB, Dinarello CA.

Rheumatology (Oxford). 2017 Dec 1;56(12):2256. doi: 10.1093/rheumatology/kex348. No abstract available.

42.

The Effects of Selective Hematopoietic Expression of Human IL-37 on Systemic Inflammation and Atherosclerosis in LDLr-Deficient Mice.

Hoeke G, Khedoe PPSJ, van Diepen JA, Pike-Overzet K, van de Ven B, Vazirpanah N, Mol I, Hiemstra PS, Staal FJT, Stienstra R, Netea MG, Dinarello CA, Rensen PCN, Berbée JFP.

Int J Mol Sci. 2017 Aug 9;18(8). pii: E1672. doi: 10.3390/ijms18081672.

43.

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.

Choi SW, Braun T, Henig I, Gatza E, Magenau J, Parkin B, Pawarode A, Riwes M, Yanik G, Dinarello CA, Reddy P.

Blood. 2017 Oct 12;130(15):1760-1767. doi: 10.1182/blood-2017-06-790469. Epub 2017 Aug 7.

44.

A guiding map for inflammation.

Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA.

Nat Immunol. 2017 Jul 19;18(8):826-831. doi: 10.1038/ni.3790.

45.

Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases.

Damen MSMA, Popa CD, Netea MG, Dinarello CA, Joosten LAB.

Atherosclerosis. 2017 Sep;264:83-91. doi: 10.1016/j.atherosclerosis.2017.07.005. Epub 2017 Jul 6. Review.

46.

IL-32γ promotes the healing of murine cutaneous lesions caused by Leishmania braziliensis infection in contrast to Leishmania amazonensis.

Gomes RS, Silva MVT, Dos Santos JC, de Lima Silva LL, Batista AC, Machado JR, Teixeira MM, Dorta ML, de Oliveira MAP, Dinarello CA, Joosten LAB, Ribeiro-Dias F.

Parasit Vectors. 2017 Jul 14;10(1):336. doi: 10.1186/s13071-017-2268-4.

47.

IL-37 Causes Excessive Inflammation and Tissue Damage in Murine Pneumococcal Pneumonia.

Schauer AE, Klassert TE, von Lachner C, Riebold D, Schneeweiß A, Stock M, Müller MM, Hammerschmidt S, Bufler P, Seifert U, Dietert K, Dinarello CA, Nold MF, Gruber AD, Nold-Petry CA, Slevogt H.

J Innate Immun. 2017;9(4):403-418. doi: 10.1159/000469661. Epub 2017 Jun 10.

48.

Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome.

Neudecker V, Haneklaus M, Jensen O, Khailova L, Masterson JC, Tye H, Biette K, Jedlicka P, Brodsky KS, Gerich ME, Mack M, Robertson AAB, Cooper MA, Furuta GT, Dinarello CA, O'Neill LA, Eltzschig HK, Masters SL, McNamee EN.

J Exp Med. 2017 Jun 5;214(6):1737-1752. doi: 10.1084/jem.20160462. Epub 2017 May 9.

49.

Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway.

Crişan TO, Cleophas MCP, Novakovic B, Erler K, van de Veerdonk FL, Stunnenberg HG, Netea MG, Dinarello CA, Joosten LAB.

Proc Natl Acad Sci U S A. 2017 May 23;114(21):5485-5490. doi: 10.1073/pnas.1620910114. Epub 2017 May 8.

50.

IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation.

Novick D, Dinarello CA.

J Allergy Clin Immunol. 2017 Jul;140(1):316. doi: 10.1016/j.jaci.2017.02.037. Epub 2017 Apr 28. No abstract available.

PMID:
28457594

Supplemental Content

Loading ...
Support Center